Summary
Definition
History and exam
Key diagnostic factors
- jugular venous distention
- lower extremity edema
- history of a chronic inflammatory condition, chronic infection, familial periodic fever syndrome
- history of monoclonal gammopathy of undetermined significance (MGUS)
- periorbital purpura
- eyelid petechiae
- macroglossia
Other diagnostic factors
- fatigue
- weight loss
- dyspnea on exertion
- peripheral neuropathy
- autonomic neuropathy
- claudication
- nausea or vomiting
- abdominal cramps
- alternating bowel habit
- steatorrhea
- lightheaded
- submandibular salivary gland enlargement
- hepatomegaly
- shoulder pad sign
- diffuse muscular weakness
- orthostatic hypotension
- carpal tunnel syndrome
- musculoskeletal disorders
Risk factors
- monoclonal gammopathy of undetermined significance (MGUS)
- inflammatory polyarthropathy
- chronic infections
- inflammatory bowel disease
- familial periodic fever syndromes
- Castleman disease
Diagnostic tests
1st tests to order
- serum immunofixation electrophoresis
- urine immunofixation electrophoresis (using 24-hour urine collection)
- serum immunoglobulin free light chain assay
- CBC with differential
- peripheral blood smear
- serum quantitative immunoglobulins
- serum protein electrophoresis
- comprehensive metabolic profile
- urine protein electrophoresis (using 24-hour urine collection)
- 24-hour total urine protein
- orthostatic vital sign assessment
- tissue biopsy
- fluorescence in situ hybridization (FISH)
Tests to consider
- mass spectrometry
- immuno-electron microscopy
- immunohistochemical studies
- genetic testing
- serum troponin T or I
- N-terminal pro-B-type natriuretic peptide (NT‐proBNP)
- lipid panel
- coagulation studies
- ECG
- echocardiogram (with tissue Doppler and global longitudinal strain)
- cardiac MRI
- cardiac scintigraphy
- electromyogram/nerve conduction studies
- endocrine tests
- pulmonary function tests
- computed tomography (CT) scan
- fluorodeoxyglucose positron emission tomography (FDG-PET)/CT
- skeletal survey
- abdominal ultrasound
- gastric emptying scan
- upper and lower endoscopy
- 123I-labeled serum amyloid P (SAP) scintigraphy
Treatment algorithm
immunoglobulin light chain (AL) amyloidosis
secondary (AA) amyloidosis (non-familial)
familial periodic fever syndromes
transthyretin (TTR) amyloidosis
refractory or relapsed AL amyloidosis
Contributors
Authors
Morie A. Gertz, MD, MACP
Seidler Jr. Professor of Medicine
Consultant in Hematology
Chair Emeritus of the Department of Medicine
Mayo Distinguished Clinician
Mayo Clinic College of Medicine
Rochester
MN
Disclosures
MAG has received personal fees from Ionis/Akcea, Alnylam, Prothena, Janssen, Annexon, Appellis, Amgen, Medscape, Physicians Education Resource, and Research to Practice; and grants and personal fees from Spectrum. MAG has received personal fees from AbbVie and Celgene for a Data Safety Monitoring board, and personal fees from Sanofi for workforce training. MAG has received speaker fees from Teva, Johnson & Johnson, Medscape, and DAVA Oncology; and advisory board fees from Pharmacyclics and Procalara. MAG has participated in the development of educational materials for the i3Health Educational Program development. MAG has received royalties from Springer Publishing. MAG has received grant funding from the Amyloidosis Foundation, International Waldenstrom's Macroglobulinemia Foundation, and National Cancer Institute (SPORE MM SPORE 5P50 CA186781-04). MAG has stock options in Attralus (formerly known as Aurora Bio). MAG is an author of references cited in this topic.
Peer reviewers
Donna Reece, MD
Associate Professor of Medicine
Director
Program for Multiple Myeloma and Related Diseases
Princess Margaret Hospital
Toronto
Ontario
Canada
Disclosures
DR has been reimbursed by Millennium Pharmaceuticals, Inc and Johnson & Johnson, the manufacturers of bortezomib, for attending several conferences, for speaking at educational meetings, and for consulting work. She has also been reimbursed by Celgene, the manufacturer of lenalidomide and thalidomide, for attending several symposia and serving as a speaker.
Jeffrey Zonder, MD
Assistant Professor of Medicine and Oncology
Division of Hematology/Oncology
Wayne State University School of Medicine
Barbara Ann Karmanos Cancer Institute
Detroit
MI
Disclosures
JZ declares that he has no competing interests.
References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: systemic light chain amyloidosis [internet publication].Full text
Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016 Feb;29(suppl 1):S14-26.Full text Abstract
Wechalekar AD, Cibeira MT, Gibbs SD, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023 Mar;30(1):3-17.Full text Abstract
Sanchorawala V, Boccadoro M, Gertz M, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2022 Mar;29(1):1-7. Abstract
Muchtar E, Dispenzieri A, Gertz MA, et al. Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted Ttherapy (mSMART) consensus statement 2020 update. Mayo Clin Proc. 2021 Jun;96(6):1546-77.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Hypertrophic cardiomyopathy (HCM)
- Membranous glomerulopathy
- Monoclonal gammopathy of undetermined significance (MGUS)-associated neuropathy
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: systemic light chain amyloidosis
- NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation (HCT)
More Guidelines
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer